



Fasting and post-oral-glucose-load levels of
methylglyoxal are associated with microvascular, but
not macrovascular, disease in individuals with and
without (pre)diabetes
Citation for published version (APA):
Hanssen, N. M. J., Scheijen, J. L. J. M., Houben, A. J. H. M., van de Waarenburg, M., Berendschot, T. T.
J. M., Webers, C. A. B., Reesink, K. D., van Greevenbroek, M. M. J., van der Kallen, C., Schaper, N. C.,
Schram, M. T., Henry, R. M. A., Stehouwer, C. D. A., & Schalkwijk, C. G. (2021). Fasting and post-oral-
glucose-load levels of methylglyoxal are associated with microvascular, but not macrovascular, disease in
individuals with and without (pre)diabetes: The Maastricht Study. Diabetes & Metabolism, 47(1), [101148].
https://doi.org/10.1016/j.diabet.2020.02.002





Publisher's PDF, also known as Version of record
Document license:
Taverne
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.




Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 02 Nov. 2021
Diabetes & Metabolism xxx (2020) xxx–xxx
G Model
DIABET-101148; No. of Pages 9Original article
Fasting and post-oral-glucose-load levels of methylglyoxal are
associated with microvascular, but not macrovascular, disease in
individuals with and without (pre)diabetes: The Maastricht Study
N.M.J. Hanssen a,b,*, J.L.J.M. Scheijen a,b, A.J.H.M. Houben a,b, M. van de Waarenburg a,b,
T.T.J.M. Berendschot c, C.A.B. Webers c, K.D. Reesink b,d, M.M.J. van Greevenbroek a,b,
C. van der Kallen a,b, N.C. Schaper a,b, M.T. Schram a,b,e, R.M.A. Henry a,b,e,
C.D.A. Stehouwer a,b, C.G. Schalkwijk a,b
a Department of Internal Medicine, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands
b School for Cardiovascular Diseases (CARIM), Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands
c Department of Ophthalmology, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands
d Department of Biomedical Engineering, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands
e Heart and Vascular Centre, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands
A R T I C L E I N F O
Article history:
Received 17 December 2019
Received in revised form 25 January 2020







A B S T R A C T
Aims. – Reactive dicarbonyl compounds, such as methylglyoxal (MGO), rise during an oral glucose
tolerance test (OGTT), particularly in (pre)diabetes. Fasting MGO levels are associated with chronic
kidney disease (CKD) and cardiovascular disease (CVD) in patients with poorly controlled type 2 diabetes
mellitus (T2DM). Yet, whether fasting or post-OGTT plasma MGO levels are associated with vascular
disease in people with (pre)diabetes is unknown.
Methods. – Subjects with normal glucose metabolism (n = 1796; age: 57.9  8.2 years; 43.3% men),
prediabetes (n = 478; age: 61.6  7.6 years; 54.0% men) and T2DM (n = 669; age: 63.0  7.5 years; 67.0%
men) from the Maastricht Study underwent OGTTs. Plasma MGO levels were measured at baseline and 2 h
after OGTT by mass spectrometry. Prior CVD was established via questionnaire. CKD was reflected by
estimated glomerular filtration rate (eGFR) and albuminuria; retinopathy was assessed using retinal
photographs. Data were analyzed using logistic regression adjusted for gender, age, smoking, systolic blood
pressure, total-to-HDL cholesterol ratio, triglycerides, HbA1c, BMI and medication use. Odd ratios (ORs) were
expressed per standard deviation of LN-transformed MGO.
Results. – Fasting and post-OGTT MGO levels were associated with higher ORs for albuminuria  30 mg/
24 h [fasting: 1.12 (95% CI: 0.97–1.29); post-OGTT: 1.19 (1.01–1.41)], eGFR < 60 mL/min/1.73 m2
[fasting: 1.58 (95% CI: 1.38–1.82), post-OGTT: 1.57 (1.34–1.83)] and retinopathy [fasting: 1.59 (95% CI:
1.01–2.53), post-OGTT: 1.38 (0.77–2.48)]. No associations with prior CVD were found.
Conclusion. – Fasting and post-OGTT MGO levels were associated with microvascular disease, but not
prior CVD. Thus, therapeutic strategies directed at lowering MGO levels may prevent microvascular
disease.
C 2020 Elsevier Masson SAS. All rights reserved.
Available online at
ScienceDirect
www.sciencedirect.comAbbreviations: 3-DG, 3-deoxyglucosone; AGEs, advanced glycation end-products;
BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular
filtration rate; GO, glyoxal; OGTT, oral glucose tolerance test; HDL, high-density
lipoprotein; MGO, methylglyoxal; UPLC-MS/MS, ultra-high-performance liquid
chromatography/tandem mass spectrometry; UAE, urinary albumin excretion.
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Type 2 diabetes mellitus (T2DM) remains a leading risk factor
for macro- and microvascular diseases, such as cardiovascular
disease (CVD) [1], chronic kidney disease (CKD) and blindness. A
key mediator in the association between diabetes and vascular
disease may be the formation of dicarbonyl compounds, reactive
glucose metabolites that interact with proteins to form advancedst-oral-glucose-load levels of methylglyoxal are associated with
d without (pre)diabetes: The Maastricht Study. Diabetes Metab
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(GO) and 3-deoxyglucosone (3-DG) have been identified as major
dicarbonyl compounds [3]. Of these, MGO has proved to be the
most reactive dicarbonyl, and is a potential driver of diabetes
complications [4,5] and CVD [6]. Dicarbonyls can damage
endothelium, leading to prolonged endothelial activation and
impaired vasorelaxation [5]. Indeed, it was previously shown that
fasting plasma MGO levels are associated with plasma markers of
microvascular endothelial dysfunction (ED) in patients with type
1 diabetes (T1DM) [7]. Moreover, higher levels of fasting plasma
MGO are associated with incident CVD and prevalent CKD in
patients with either T1DM [7] or T2DM [8]. However, it remains
unclear whether these findings extend to prediabetes and normal
glucose metabolism.
Previously, it was found that plasma dicarbonyls increase with
glucose excursions after an oral glucose tolerance test (OGTT) or a
mixed meal [9]. As post-OGTT plasma glucose levels are more
strongly associated with incident CVD than are fasting plasma
glucose levels [10], our hypothesis was that post-load rather than
fasting levels of MGO might also be more strongly associated with
vascular outcomes. These considerations are important as peak
MGO levels can be reduced by interventions that curtail
(postprandial) glucose excursions [9] and compounds with
MGO-quenching properties, such as pyridoxamine [11], and
carnosine or its analogues [12,13].
Therefore, the present study investigated, in subjects with
NGM, prediabetes and T2DM, and the cross-sectional associations
of fasting and post-OGTT plasma levels of MGO, and two other
major dicarbonyls (GO and 3-DG), with CVD and two markers of
subclinical macrovascular disease–the ankle–brachial index (ABI)
and carotid intima–media thickness (cIMT)–as well as associations
with microvascular disease (CKD, retinopathy) and markers of
microvascular endothelial dysfunction (plasma microvascular
endothelial activation score, retinal arteriolar and venular dilata-
tion, heat-induced skin hyperaemia).
Methods
Study population
Data from the Maastricht Study, an observational prospective
population-based cohort study, were enriched by including
patients with T2DM. The rationale and design of that study have
been described previously [14]. In brief, the study focuses on the
aetiology, pathophysiology, complications and comorbidities of
T2DM, and is characterized by an extensive phenotyping approach.
Those eligible for participation were all individuals aged 40 to
75 years living in the southern part of the Netherlands. Participants
were recruited through mass media campaigns, municipal
registries and regional diabetes patient registries via mailings.
Recruitment was stratified according to known T2DM status, with
an oversampling of patients with T2DM for reasons of efficiency.
The present report includes data from 3451 participants who
completed the baseline survey between November 2010 and
September 2013; examinations of each participant were per-
formed within a time window of 3 months.
The study was approved by the institutional medical ethics
committee (NL31329.068.10) and Minister of Health, Welfare and
Sport of the Netherlands (permit number: 131088-105234-PG). All
participants gave their written informed consent.
Oral glucose tolerance tests
All subjects underwent a 75-g 2-h OGTT after an overnight fast,
except for those taking insulin or with a fasting glucosePlease cite this article in press as: Hanssen NMJ, et al. Fasting and po
microvascular, but not macrovascular, disease in individuals with an
(2020), https://doi.org/10.1016/j.diabet.2020.02.002level > 11.0 mmol/L (as determined by finger-prick test) for safety
reasons. For all included subjects, fasting glucose levels and
information on their diabetes medications were used to determine
their glucose metabolic status. This status was defined according to
World Health Organization 2006 criteria as either normal glucose
metabolism (NGM), impaired fasting glucose (IFG) and impaired
glucose tolerance (IGT), which were combined as impaired glucose
metabolism (IGM), also known as prediabetes, and T2DM.
Dicarbonyl levels and other measurements
Plasma levels of MGO, GO and 3-DG were measured by ultra-
high-performance liquid chromatography and tandem mass
spectrometry (UPLC-MS/MS) [15] at T = 0 min and T = 120 min
during OGTT. In brief, ethylenediaminetetraacetic acid (EDTA)
plasma samples (25 mL) were mixed with 75 mL of d8-O-
phenylenediamine (oPD; 10 mg of oPD in 10 mL of 1.6 mol/L
perchloric acid) in an Eppendorf cup. After overnight (20 h)
reaction at room temperature and shielded from light, 10 mL of
internal standard stock solution was added. Samples were mixed
and subsequently centrifuged for 20 min at 21,000 g at a
temperature of 4 8C; 10 mL was injected for UPLC-MS/MS analysis.
Plasma samples were then stored at -80 8C until needed for
analysis. Interassay variations for MGO, GO and 3-DG were 4.3%,
5.1% and 2.2%, respectively [15].
Prior CVD and markers of macrovascular disease
Presence of CVD was assessed by self-reported questionnaire
[14]. The VP-2000 vascular system (Omron, Kyoto, Japan) was used
to determine the ABI by measuring systolic blood pressure at the
brachial artery of the left and right arms as well as above the left
and right ankle joints [14]. Values in the leg with the lowest
available index were also included. An ABI < 0.9 was used as the
cut-off value indicative of peripheral arterial disease [16]. The cIMT
was measured as described previously elsewhere [17], and the
structural properties of the carotid artery were determined using
an ultrasound scanner equipped with a 7.5-MHz linear probe
(MyLab 70, Esaote Europe B.V., Maastricht, The Netherlands).
Markers of CKD
In addition, 24-h urinary albumin excretion (UAE) was measured
twice: UAE values 30–300 mg/24 h indicated microalbuminuria,
whereas > 300 mg/24 h indicated macroalbuminuria. For our main
analyses of albuminuria, micro- and macroalbuminuria were
combined. The estimated glomerular filtration rate (eGFR) was
calculated (in mL/min/1.73 m2) using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation based on both
serum creatinine and serum cystatin C [18].
Retinopathy
The presence of retinopathy was assessed in both eyes by
fundus photographs taken with an automated fundus camera
(AFC-230 digital retinal camera; Nidek Co., Ltd., Gamagori, Aichi,
Japan) [14]. Retinopathy was graded according to the diabetic
retinopathy (DR) disease severity scale and International Clinical
DR Disease Severity Scale (American Academy of Ophthalmology
Retina/Vitreous Panel, 2014).
Measurements of microvascular endothelial dysfunction
Retinal arteriolar and venular dilatation responses to flicker
pupil light, which are thought to be related to nutritional demands
of activated retinal neurons, were measured in a dimly lit roomst-oral-glucose-load levels of methylglyoxal are associated with
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Germany). For each participant, either the left or right eye was
randomly measured. The percentage dilatation over baseline
was based on the average dilatation achieved at 10-s and 40-s
time points during the flicker stimulation period [19].
The heat-induced skin hyperaemic response, thought to be
related to skin metabolic and thermoregulatory function, is
considered a marker of endothelial microvascular function. Skin
blood flow was measured, as described previously, by means of
laser Doppler velocimetry (PeriFlux 5000; Perimed AB, Järfälla,
Sweden), using a thermostatic laser Doppler probe (PF457;
Perimed) on the dorsal side of the left wrist. The heat-induced
skin hyperaemic response was expressed as the percentage
increase in average perfusion units over the average baseline
perfusion units during the 23-min heating phase [19].
As described previously elsewhere [20], plasma biomarkers of
microvascular ED [soluble vascular cell adhesion molecule-1
(sVCAM-1), soluble intercellular adhesion molecule (sICAM-1),
soluble E-selectin (sE-selectin), von Willebrand factor (vWF)] were
measured, the former three biomarkers in EDTA plasma samples
using commercially available 4-plex sandwich immunoassay kits
(Meso Scale Diagnostics LLC, Rockville, MD, USA), and the latter
(vWF) in citrated plasma using sandwich enzyme-linked immu-
nosorbent assay (ELISA; DAKO, Jena, Germany). For the present
study, intra- and interassay coefficients of variation were 3.5% and
5.9% for sVCAM-1, 2.5% and 5.3% for sICAM-1, 6.4% and 6.0% for
sE-selectin, and 3.2% and 5.4% for vWF. These markers were
combined as a composite Z-score for our primary analyses.
Measurement of potential confounders
Weight, height, body mass index (BMI), blood pressure, plasma
glucose levels, glycohaemoglobin A1c (HbA1c) and plasma lipid
profiles were measured as described elsewhere [14]. Smoking
status (never, former, current) was assessed by questionnaire, and
the use of lipid-modifying, antihypertensive and glucose-lowering
medications was assessed during a medication interview.
Selection of study participants for analysis
For the present study analyses, data from the first 3451 parti-
cipants of the Maastricht Study were used, after first excluding
participants with either T1DM (n = 37) or diabetes of undeter-
mined type (n = 4). Next were excluded those individuals for
whom plasma samples to measure dicarbonyls were not available
at either T = 0 min (n = 121) or T = 120 min (n = 393) of OGTT and
those with missing confounders (n = 50), thereby arriving at
2943 participants (Fig. 1). However, for logistical reasons, not all
outcomes could be assessed in all participants. Prior CVD was only
available for 2920 participants, ABI for 2720, cIMT for 2503,
albuminuria for 2919, eGFR for 2943, retinopathy for 2442, retinal
arteriolar average dilatation for 1985, retinal venular average
dilatation for 2017, heat-induced skin hyperaemia for 1419 and
plasma ED scores for 2924.
Statistical analyses
All analyses were performed with SPSS version 20.0 software
for Windows (IBM Corp., Armonk, NY, USA). Plasma dicarbonyl and
glucose levels, UAE and heat-induced skin hyperaemia were LN-
transformed prior to analyses to reduce the influence of potential
outliers. Logistic regression models were used to investigate cross-
sectional associations between plasma dicarbonyl and glucose
levels and the presence of CVD, ABI < 0.9, markers indicative of
CKD and retinopathy. In particular, ABI sensitivity analyses were
performed, excluding those with scores  1.3 (n = 167) or  1.4Please cite this article in press as: Hanssen NMJ, et al. Fasting and po
microvascular, but not macrovascular, disease in individuals with an
(2020), https://doi.org/10.1016/j.diabet.2020.02.002(n = 17), as such ABI values can be indicative of vascular
calcification [16]. Linear regression models were also applied to
investigate associations between fasting and post-load plasma Z-
scores for plasma dicarbonyl and glucose levels, as well as cIMT,
ABI, UAE, eGFR and markers of microvascular ED on a continuous
scale. All models were adjusted for gender, age and glucose
metabolic status (model 1), with further adjustments performed
for cardiovascular risk factors: BMI, systolic blood pressure, total-
to-high-density lipoprotein cholesterol (HDL-C) ratio, triglycer-
ides, smoking status, and lipid-modifying, antihypertensive and
glucose-lowering treatments (model 2). Finally, whether glycae-
mic control influenced these associations was investigated after
adjusting model 2 for HbA1c levels (model 3).
Interaction analyses also evaluated whether any of the
associations found differed between men and women (gen-
der  MGO, GO or 3-DG) or according to glucose metabolic status
(IGM or T2DM  MGO, GO or 3-DG) by adding interaction terms to
model 3. Pinteraction < 0.10 was considered statistically significant
for these analyses.
Results
Table I presents the clinical characteristics of the Maastricht
Study participants included in the present analyses according to
glucose metabolic status.
Fasting and post-OGTT dicarbonyl levels
Compared with NGM, fasting plasma MGO levels were higher in
prediabetes and T2DM subjects (Ptrend < 0.05); this difference
appeared to be more evident after OGTT at T = 120 min (Table I).
However, no increase in MGO levels was observed after OGTT
in those with NGM (D -45.0  99.0 nmol/L) or prediabetes
(D -33.0  99.8 nmol/L), whereas post-OGTT plasma MGO levels
were increased in T2DM patients (D 22.4  133.8 nmol/L; Table I). In
addition, plasma GO levels were significantly higher in those with
prediabetes and T2DM after OGTT, but not at baseline (Table 1),
whereas 3-DG and glucose levels were increased in these subjects
both before and after OGTT (Table 1).
Fasting and post-OGTT plasma dicarbonyls and prior CVD, ABI and
cIMT
On first investigating the associations between fasting
(T = 0 min) and post-OGTT (T = 120 min) plasma levels of MGO,
GO and 3-DG and the presence of CVD and subclinical markers of
macrovascular disease (ABI, cIMT), no consistent associations were
found overall between fasting and post-OGTT plasma levels of
MGO, GO and 3-DG and either prior CVD, ABI (cut-off point
of < 0.9 or continuous scale) or cIMT (Table 2). When those with an
ABI  1.4 or  1.3 were excluded, the associations between plasma
dicarbonyls and ABI did not change (data not shown). In addition,
no consistent interactions were found for either gender or glucose
metabolic status (data not shown).
Fasting and post-OGTT plasma dicarbonyls and presence of
albuminuria, reduced eGFR and retinopathy
Higher fasting plasma MGO levels were associated with greater
odds of having macroalbuminuria independently of gender, age
and glucose metabolic status (Table 3, model 1). This association
was not attenuated after further adjusting for total-to-HDL-C ratio,
triglycerides, lipid-modifying treatment, smoking status, systolic
blood pressure, BMI, and blood pressure-lowering and glucose-
lowering treatments (Table 3, model 2) or HbA1c (Table 3, model 3).st-oral-glucose-load levels of methylglyoxal are associated with
d without (pre)diabetes: The Maastricht Study. Diabetes Metab
Fig. 1. Flow chart of the study population-selection process.
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found with macroalbuminuria as with fasting plasma MGO levels
in model 1, which was attenuated and no longer statistically
significant after additional adjustments (Table 3, models 2–3).
Moreover, similar but weaker associations were found between
fasting plasma MGO levels and albuminuria (Table 3, model 1),
which were attenuated and of borderline significance after furtherPlease cite this article in press as: Hanssen NMJ, et al. Fasting and po
microvascular, but not macrovascular, disease in individuals with an
(2020), https://doi.org/10.1016/j.diabet.2020.02.002model adjustments (Table 3, models 2–3). On the other hand,
associations between post-OGTT plasma MGO levels and greater
odds of having albuminuria remained statistically significant
throughout all statistical models (Table 3, models 1–3). However,
when additional adjustments were made for the association
between post-OGTT plasma MGO levels and albuminuria for
fasting MGO levels, the point estimate of this association appearedst-oral-glucose-load levels of methylglyoxal are associated with
d without (pre)diabetes: The Maastricht Study. Diabetes Metab
Table 1
Participant characteristics stratified according to glucose metabolism status.
NGM (n = 1796) Prediabetes (n = 478) T2DM (n = 669) Ptrend
Age (years) 57.9  8.2 61.6  7.6 63.0  7.5 < 0.05
Gender (male, %) 43.3 54.0 67.0 < 0.05
HbA1c (%) 5.4  0.3 5.7  0.4 6.6  0.6 < 0.05
HbA1c (mmol/mol) 36.1  3.8 38.8  4.4 48.4  7.0 < 0.05
Body mass index (kg/m2) 25.6  3.6 27.7  4.2 29.5  4.8 < 0.05
Total cholesterol (mmol/L) 5.6  1.0 5.4  1.1 4.5  1.0 < 0.05
HDL cholesterol (mmol/L) 1.6  0.5 1.5  0.4 1.3  0.4 < 0.05
Triglycerides (mmol/L) 1.1 (0.8–1.5) 1.4 (1.0–1.8) 1.5 (1.2–2.1) < 0.05
Systolic blood pressure (mmHg) 130.7  17.3 137.2  17.0 141.4  17.4 < 0.05
Diastolic blood pressure (mmHg) 78.1  9.6 78.1  9.6 77.8  9.5 < 0.05
Smoking status [never, ex, current (%)] (39.2, 48.2, 12.6) (30.3, 57.3, 12.3) (29.7, 56.2, 14.1) < 0.05
Glucose-lowering treatment (%) 0 0 71.4 < 0.05
Lipid-lowering treatment (%) 17.2 34.9 71.6 < 0.05
Antihypertensive medication (%) 22.5 44.8 68.8 < 0.05
Oral glucose tolerance test
T = 0 min glucose (mmol/L) 5.2 (4.9–5.5) 6.1 (5.5–6.4) 7.3 (6.6–8.1) < 0.05
T = 120 min glucose (mmol/L) 5.4 (4.6–6.2) 8.4 (7.2–9.4) 14.4 (11.9–17.2) < 0.05
D Glucose (mmol/L) 0.2  1.1 2.2  2.0 7.0  3.4 < 0.05
T = 0 min MGO (nmol/L) 308.3 (269.5–358.1) 325.5 (283.6–383.5) 346.0 (300.4–399.8) < 0.05
T = 120 min MGO (nmol/L) 262.3 (229.0–305.7) 298.2 (259.7–343.5) 366.2 (319.7–437.0) < 0.05
D MGO (nmol/L) 45.77  99.1 33.4  99.8 22.4  133.8 < 0.05
T = 0 min GO (nmol/L) 1216.6 (1018.0–1476.5) 1209.3 (1025.6–1455.8) 1182.8 (1007.5–1488.9) 0.75
T = 120 min GO (nmol/L) 1159.0 (976.0–1402.3) 1246.8 (1058.5–1463.1) 1476.6 (1246.4–1749.5) < 0.05
D GO (nmol/L) 56.3  538.1 2.5  562.9 281.5  663.0 < 0.05
T = 0 min 3-DG (nmol/L) 1141.9 (1044.0–1263.6) 1295.4 (1167.6–1468.6) 1630.2 (1454.2–1886.0) < 0.05
T = 120 min 3-DG (nmol/L) 1190.9 (1014.7–1370.5) 1733.0 (1483.5–1999.3) 2891.5 (2416.1–3389.3) < 0.05
D 3-DG (nmol/L) 43.7  260.0 402.5  378.2 1213.8  617.0 < 0.05
Macrovascular disease markers
Previous CVD (%) 12.0 14.0 25.3 < 0.05
Ankle–brachial index (ABI) 1.2  0.1 1.1  0.1 1.1  0.1 < 0.05
ABI < 0.9 (%) 1.3 1.6 3.9 < 0.05
cIMT (mm) 842.5  148.3 872.6  157.3 890.1  172.2 < 0.05
Microvascular disease markers
Presence of retinopathy (%) 0.1 0.3 1.9 < 0.05
eGFR (mL/min/1.73 m2) 80.5  14.1 79.6  14.1 81.6  18.0 0.17
eGFR < 60 mL/min/1.73 m2 (%) 5.4 7.1 10.0 < 0.05
UAE (mg/mmol/24 h) 0.5 (0.2–0.8) 0.5 (0.3–0.8) 0.7 (0.4–1.3) < 0.05
Microalbuminuria (%) 3.7 5.9 14.3 < 0.05
Macroalbuminuria (%) 0.4 0.8 0.9 < 0.05
Microvascular endothelial dysfunction markers
Flicker pupil light-induced arteriolar dilatation (%) 3.4  2.8 3.0  2.8 2.5  2.6 < 0.05
Flicker pupil light-induced venular dilatation (%) 3.9  2.2 4.0  2.2 3.7  2.2 0.15
Heat-induced skin hyperaemia (%) 1085.8 (639.3–1618.8) 995.4 (575.7–1541.6) 824.6 (517.3–1249.2) < 0.05
von Willebrand factor (%) 125.4  44.2 136.4  48.1 140.5  52.0 < 0.05
sE-selectin (ng/mL) 102.1  46.7 118.8  55.9 143.7  74.2 < 0.05
sICAM (ng/mL) 335.4  79.3 360.7  97.9 380.7  111.7 < 0.05
sVCAM (ng/mL) 413.1  86.5 424.2  103.4 447.3  107.3 < 0.05
Plasma microvascular score (Z-score) 0.2  0.8 0.1  1.1 0.5  1.2 < 0.05
Data are expressed as means  standard deviation, interquartile ranges or percentages as appropriate; Ptrend was calculated by linear regression or Chi2 analyses; skewed variables
were LN-normalized prior to analyses; NGM: normal glucose metabolism; T2DM: type 2 diabetes mellitus; HbA1c: glycated haemoglobin; HDL: high-density lipoprotein; MGO:
methylglyoxal; GO: glyoxal; 3-DG: 3-deoxyglucosone; CVD: cardiovascular disease; cIMT: carotid intima–media thickness; eGFR: estimated glomerular filtration rate; UAE: urinary
albumin excretion; sE-selectin: soluble E-selectin; sICAM: soluble intercellular adhesion molecule; sVCAM: soluble vascular adhesion molecule
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[OR: 1.16 (95% CI: 0.96–1.39) vs. 1.19 (1.01–1.41)]. Higher fasting
and post-OGTT plasma MGO levels were also associated with
higher UAE when analyzed on a continuous scale (Table S1; see
supplementary materials associated with this material online).
In line with these findings, higher fasting plasma MGO levels
were associated with greater odds of having a lower eGFR
(< 60 mL/min/1.73 m2) after adjusting for gender, age and glucose
metabolic status (Table 3, model 1), an association that was not
attenuated when the model was further adjusted (Table 3, models
2–3). Point estimates for these associations were similar for post-
OGTT plasma MGO levels (Table 3, models 1–3). However, after
adjusting for the association between post-OGTT plasma MGO
levels and a decreased eGFR with fasting MGO levels, it was found
that the point estimate weakened [OR: 1.34 (95% CI: 1.12–1.60) vs.
1.57 (1.34–1.83)]. Higher fasting and post-OGTT plasma MGOPlease cite this article in press as: Hanssen NMJ, et al. Fasting and po
microvascular, but not macrovascular, disease in individuals with an
(2020), https://doi.org/10.1016/j.diabet.2020.02.002levels were also significantly associated with a lower eGFR when
analyzed on a continuous scale (Table S1).
Even though retinopathy was numerically infrequent
(n = 14 cases), our study found that higher fasting plasma MGO
levels were associated with greater odds of having retinopathy,
which became statistically significant in the fully adjusted model
(Table 3, model 3). As for post-OGTT plasma MGO levels, point
estimates of these associations indicated a similar direction, but
were somewhat weaker and not statistically significant (Table 3,
models 1–3).
As regards either fasting or post-OGTT plasma levels of GO, no
significant associations were found with the presence of albumin-
uria, eGFR < 60 mL/min/1.73 m2 or retinopathy. However, an
association was revealed between higher fasting, but not post-
OGTT, plasma levels of GO and a lower eGFR when analyzed on a
continuous scale (Table S1).st-oral-glucose-load levels of methylglyoxal are associated with
d without (pre)diabetes: The Maastricht Study. Diabetes Metab
Table 2
Associations between plasma dicarbonyl levels and markers of macrovascular disease.
Model Previous CVD (n = 448) ABI < 0.9 (n = 52) ABI (on continuous scale) cIMT
MGO T = 0 min 1 1.00 (0.90–1.11) 0.78 (0.57–1.06) 0.03 (0.07 to 0.01) 0.02 (0.02 to 0.05)
2 0.99 (0.89–1.11) 0.75 (0.55–1.02) 0.02 (0.05 to 0.02) 0.01 (0.03 to 0.05)
3 0.99 (0.88–1.11) 0.73 (0.53–1.01) 0.01 (0.05 to 0.03) 0.01 (0.03 to 0.04)
MGO T = 120 min 1 0.98 (0.87–1.11) 0.83 (0.59–1.15) 0.03 (0.07 to 0.01) 0.01 (0.03 to 0.05)
2 0.99 (0.87–1.12) 0.79 (0.56–1.12) 0.02 (0.06 to 0.02) 0.00 (0.04 to 0.04)
3 0.98 (0.86–1.11) 0.76 (0.53–1.09) 0.01 (0.06 to 0.03) 0.00 (0.05 to 0.04)
GO T = 0 min 1 0.90 (0.81–1.00) 0.99 (0.75–1.30) 0.01 (0.03 to 0.05) 0.01 (0.02 to 0.05)
2 0.95 (0.85–1.06) 1.05 (0.80–1.38) 0.01 (0.05 to 0.03) 0.02 (0.02 to 0.05)
3 0.95 (0.85–1.06) 1.05 (0.80–1.38) 0.01 (0.05 to 0.03) 0.02 (0.02 to 0.05)
GO T = 120 min 1 0.90 (0.80–1.00) 0.76 (0.57–1.03) 0.06 (0.02 to 0.09) 0.00 (0.04 to 0.04)
2 0.96 (0.86–1.08) 0.81 (0.60–1.09) 0.03 (0.01 to 0.07) 0.00 (0.04 to 0.04)
3 0.96 (0.86–1.08) 0.81 (0.60–1.09) 0.03 (0.01 to 0.07) 0.00 (0.04 to 0.04)
3-DG T = 0 min 1 1.06 (0.92–1.22) 0.89 (0.62–1.30) 0.05 (0.10 to 0.00) 0.01 (0.04 to 0.06)
2 1.01 (0.87–1.18) 0.79 (0.53–1.18) 0.03 (0.08 to 0.03) 0.00 (0.05 to 0.05)
3 0.99 (0.84–1.16) 0.74 (0.49–1.13) 0.01 (0.07 to 0.04) 0.01 (0.07 to 0.05)
3-DG T = 120 min 1 0.99 (0.83–1.18) 0.87 (0.56–1.36) 0.05 (0.11 to 0.02) 0.01 (0.08 to 0.05)
2 0.92 (0.76–1.12) 0.71 (0.44–1.17) 0.02 (0.08 to 0.05) 0.04 (0.10 to 0.03)
3 0.89 (0.73–1.10) 0.69 (0.40–1.11) 0.00 (0.07 to 0.07) 0.05 (0.11 to 0.02)
Glucose T = 0 min 1 0.87 (0.73–1.02) 1.13 (0.75–1.72) 0.02 (0.09 to 0.04) 0.01 (0.06 to 0.07)
2 0.81 (0.68–0.97) 1.06 (0.69–1.64) 0.00 (0.07 to 0.06) 0.00 (0.06 to 0.07)
3 0.75 (0.62–0.91) 1.02 (0.63–1.64) 0.03 (0.04 to 0.10) 0.01 (0.08 to 0.06)
Glucose T = 120 min 1 0.93 (0.77–1.12) 0.95 (0.59–1.53) 0.02 (0.09 to 0.05) 0.02 (0.09 to 0.05)
2 0.87 (0.71–1.07) 0.82 (0.49–1.37) 0.00 (0.07 to 0.07) 0.04 (0.11 to 0.03)
3 0.85 (0.69–1.04) 0.77 (0.45–1.33) 0.02 (0.06 to 0.09) 0.05 (0.12 to 0.03)
Data analysis by logistic [previous CVD, ankle–brachial index (ABI) < 0.9] or linear [ABI, carotid intima–media thickness (cIMT)] regression, expressed as odds ratios (previous
CVD, ABI < 0.9) or 1 standard deviation (SD) difference (cIMT, ABI) per SD increase of independent variable; plasma dicarbonyl and glucose levels LN-transformed prior to
analyses; Model 1: adjusted for age, gender, presence of impaired glucose metabolism or type 2 diabetes mellitus; Model 2: model 1 + adjusted for total-to-HDL-C ratio,
triglycerides, lipid-modifying treatment, smoking status, systolic blood pressure, blood-pressure-lowering treatment, body mass index, glucose-lowering treatment; Model
3: model 2 + adjusted for HbA1c; CVD: cardiovascular disease; MGO: methylglyoxal; GO: glyoxal; 3-DG: 3-deoxyglucosone; HDL-C: high-density lipoprotein cholesterol.
Table 3
Associations between plasma levels of dicarbonyl and markers of microvascular disease.
Model Macroalbuminuria
(> 300 mg/24 h)
(n = 17 cases)
Albuminuria
(>30 mg/24 h)
(n = 211 cases)
eGFR
(< 60 mL/min/1.73 m2)
(n = 197 cases)
Retinopathy
(n = 14 cases)
MGO T = 0 min 1 1.57 (1.14–2.17) 1.15 (1.00–1.32) 1.57 (1.37–1.79) 1.37 (0.95–1.96)
2 1.63 (1.11–2.39) 1.13 (0.98–1.30) 1.57 (1.36–1.80) 1.54 (0.98–2.44)
3 1.61 (1.10–2.38) 1.12 (0.97–1.29) 1.58 (1.38–1.82) 1.60 (1.01–2.53)
MGO T = 120 min 1 1.55 (1.00–2.40) 1.22 (1.04–1.42) 1.54 (1.32–1.79) 1.26 (0.73–2.17)
2 1.46 (0.95–2.26) 1.21 (1.02–1.42) 1.54 (1.31–1.80) 1.25 (0.69–2.25)
3 1.41 (0.90–2.21) 1.19 (1.01–1.41) 1.57 (1.34–1.83) 1.38 (0.77–2.48)
GO T = 0 min 1 1.05 (0.65–1.68) 1.01 (0.88–1.17) 1.03 (0.89–1.20) 1.51 (0.96–2.38)
2 1.09 (0.67–1.76) 1.02 (0.89–1.18) 1.07 (0.92–1.24) 1.53 (0.92–2.54)
3 1.08 (0.66–1.77) 1.02 (0.89–1.18) 1.07 (0.92–1.24) 1.57 (0.95–2.59)
GO T = 120 min 1 1.18 (0.72–1.92) 1.05 (0.90–1.23) 1.00 (0.85–1.17) 1.17 (0.68–1.99)
2 1.19 (0.72–1.97) 1.06 (0.91–1.24) 1.04 (0.89–1.22) 1.08 (0.59–1.98)
3 1.15 (0.70–1.91) 1.06 (0.90–1.23) 1.04 (0.89–1.23) 1.16 (0.63–2.13)
3-DG T = 0 min 1 2.22 (1.18–4.18) 1.16 (0.96–1.41) 1.07 (0.87–1.31) 0.90 (0.47–1.70)
2 1.96 (1.01–3.82) 1.12 (0.92–1.37) 1.01 (0.81–1.24) 0.78 (0.40–1.52)
3 1.84 (0.90–3.74) 1.09 (0.88–1.35) 1.02 (0.82–1.28) 0.88 (0.43–1.81)
3-DG T = 120 min 1 3.77 (1.60–8.84) 1.23 (0.96–1.59) 0.91 (0.71–1.18) 1.41 (0.56–3.52)
2 3.57 (1.30–9.80) 1.15 (0.88–1.51) 0.82 (0.62–1.07) 1.13 (0.45–2.87)
3 3.36 (1.18–9.58) 1.11 (0.84–1.48) 0.82 (0.62–1.08) 1.48 (0.53–4.12)
Glucose T = 0 min 1 3.47 (1.53–7.87) 1.35 (1.08–1.69) 0.89 (0.70–1.13) 0.93 (0.49–1.77)
2 2.73 (1.18–6.30) 1.30 (1.03–1.63) 0.83 (0.65–1.07) 0.75 (0.40–1.42)
3 2.72 (1.05–7.02) 1.29 (1.00–1.67) 0.83 (0.63–1.08) 0.87 (0.40–1.87)
Glucose T = 120 min 1 6.16 (1.66–22.78) 1.30 (0.99–1.70) 0.81 (0.63–1.06) 1.56 (0.58–4.22)
2 4.76 (1.20–18.92) 1.22 (0.91–1.62) 0.73 (0.56–0.96) 1.17 (0.44–3.09)
3 4.34 (1.07–17.73) 1.18 (0.88–1.59) 0.73 (0.55–0.96) 1.63 (0.52–5.14)
Data analysis by logistic regression; odds ratios expressed per standard deviation (SD) increase of independent variable; plasma dicarbonyl and glucose levels LN-
transformed prior to analyses; Model (M) 1: adjusted for age, gender, glucose metabolic status; Model 2: model 1 + adjusted for total-to-HDL-C ratio, triglycerides, lipid-
modifying treatment, smoking status, systolic blood pressure, blood-pressure-lowering treatment, body mass index, previous cardiovascular disease, glucose-lowering
treatment; Model 3: model 2 + adjusted for HbA1c; eGFR: estimated glomerular filtration rate; MGO: methylglyoxal; GO: glyoxal; 3-DG: 3-deoxyglucosone; HDL-C: high-
density lipoprotein cholesterol.
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post-OGTT plasma 3-DG levels and greater odds of having
macroalbuminuria. On the other hand, this association was not
observed for the presence of albuminuria (Table 3, models 1–3)
and, when UAE was analyzed on a continuous scale, this
association was only present for fasting plasma levels of GO. InPlease cite this article in press as: Hanssen NMJ, et al. Fasting and po
microvascular, but not macrovascular, disease in individuals with an
(2020), https://doi.org/10.1016/j.diabet.2020.02.002addition, higher post-OGTT levels of 3-DG, but not fasting plasma
3-DG levels, were associated with higher eGFR values (Table S1).
Moreover, plasma glucose levels, but not a decreased eGFR or
the presence of retinopathy were, in the present analyses,
associated with significantly greater odds of having (macro)-
albuminuria (Table 3, models 1–3). Finally, no consistent inter-st-oral-glucose-load levels of methylglyoxal are associated with
d without (pre)diabetes: The Maastricht Study. Diabetes Metab
Table 4









MGO T = 0 min 1 0.03 (0.07 to 0.02) 0.03 (0.08 to 0.01) 0.04 (0.01 to 0.09) 0.04 (0.00 to 0.07)
2 0.03 (0.07 to 0.02) 0.03 (0.07 to 0.02) 0.04 (0.01 to 0.10) 0.03 (0.00 to 0.07)
3 0.02 (0.07 to 0.02) 0.03 (0.07 to 0.02) 0.05 (0.01 to 0.10) 0.03 (0.01 to 0.06)
MGO T = 120 min 1 0.03 (0.08 to 0.02) 0.02 (0.08 to 0.03) 0.03 (0.08 to 0.02) 0.04 (0.00 to 0.08)
2 0.03 (0.08 to 0.02) 0.02 (0.07 to 0.03) 0.03 (0.08 to 0.02) 0.03 (0.01 to 0.07)
3 0.03 (0.08 to 0.03) 0.02 (0.07 to 0.04) 0.03 (0.08 to 0.03) 0.03 (0.02 to 0.07)
GO T = 0 min 1 0.02 (0.03 to 0.06) 0.05 (0.09 to 0.01) 0.06 (0.11 to 0.01) 0.01 (0.04 to 0.03)
2 0.02 (0.03 to 0.06) 0.06 (0.10 to 0.01) 0.05 (0.10 to 0.00) 0.03 (0.01 to 0.06)
3 0.02 (0.03 to 0.06) 0.06 (0.10 to 0.01) 0.05 (0.10 to 0.00) 0.03 (0.01 to 0.06)
GO T = 120 min 1 0.06 (0.09 to 0.19) 0.02 (0.06 to 0.19) 0.03 (0.02 to 0.07) 0.03 (0.07 to 0.01)
2 0.06 (0.08 to 0.20) 0.03 (0.07 to 0.02) 0.03 (0.02 to 0.08) 0.01 (0.04 to 0.03)
3 0.07 (0.08 to 0.21) 0.03 (0.07 to 0.02) 0.03 (0.02 to 0.08) 0.01 (0.05 to 0.03)
3-DG T = 0 min 1 0.07 (0.13 to 0.01) 0.03 (0.09 to 0.03) 0.14 (0.07 to 0.21) 0.07 (0.02 to 0.12)
2 0.07 (0.14 to 0.01) 0.02 (0.09 to 0.04) 0.13 (0.06 to 0.21) 0.02 (0.03 to 0.07)
3 0.07 (0.14 to 0.00) 0.02 (0.09 to 0.05) 0.16 (0.09 to 0.24) 0.01 (0.05 to 0.06)
3-DG T = 120 min 1 0.01 (0.07 to 0.09) 0.03 (0.11 to 0.05) 0.01 (0.07 to 0.09) 0.14 (0.08 to 0.20)
2 0.02 (0.07 to 0.10) 0.02 (0.10 to 0.07) 0.02 (0.07 to 0.10) 0.08 (0.02 to 0.15)
3 0.03 (0.06 to 0.11) 0.01 (0.10 to 0.07) 0.03 (0.06 to 0.11) 0.08 (0.01 to 0.14)
Glucose T = 0 min 1 0.05 (0.13 to 0.02) 0.06 (0.14 to 0.01) 0.00 (0.09 to 0.09) 0.12 (0.07 to 0.18)
2 0.06 (0.14 to 0.02) 0.06 (0.14 to 0.01) 0.01 (0.10 to 0.07) 0.06 (0.00 to 0.11)
3 0.05 (0.13 to 0.03) 0.06 (0.14 to 0.02) 0.01 (0.08 to 0.11) 0.04 (0.02 to 0.10)
Glucose T = 120 min 1 0.06 (0.03 to 0.14) 0.00 (0.09 to 0.08) 0.06 (0.03 to 0.14) 0.13 (0.06 to 0.19)
2 0.06 (0.02 to 0.15) 0.00 (0.08 to 0.09) 0.06 (0.02 to 0.15) 0.07 (0.01 to 0.14)
3 0.07 (0.01 to 0.16) 0.01 (0.08 to 0.10) 0.08 (0.01 to 0.16) 0.06 (0.00 to 0.13)
Data analysis by linear regression; regression coefficients expressed as 1 standard deviation (SD) difference in outcome per SD increase of plasma dicarbonyl or glucose; skin
hyperaemia and plasma glucose and dicarbonyl levels LN-transformed prior to analyses; Model 1: adjusted for age, gender, glucose metabolic status; Model 2: model
1 + adjusted for total-to-HDL-C ratio, triglycerides, lipid-modifying treatment, smoking status, systolic blood pressure, blood-pressure-lowering treatment, body mass index,
previous cardiovascular disease, glucose-lowering treatment; Model 3: model 2 + adjusted for HbA1c; MGO: methylglyoxal; GO: glyoxal; 3-DG: 3-deoxyglucosone; HDL-C:
high-density lipoprotein cholesterol.
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for these associations (data not shown).
Fasting and post-OGTT plasma dicarbonyls and plasma microvascular
ED, retinal arteriolar/venular average dilatation and heat-induced
skin hyperaemia
Whether plasma dicarbonyls are associated with markers of
microvascular ED and activation was also investigated. After
adjusting for gender, age and glucose metabolic status, higher
fasting and post-OGTT plasma MGO levels were associated with
higher plasma microvascular ED scores (Table 4, model 1),
although this association was attenuated and no longer significant
after further adjusting (Table 4, models 2–3). On analyzing
microvascular endothelial plasma markers separately, the main
findings were an association between higher plasma MGO and
plasma sE-selectin levels (Table S2; see supplementary materials
associated with this material online). In addition, no associations
were noted between fasting and post-OGTT plasma MGO levels,
retinal arteriolar or venular dilatation and heat-induced skin
hyperaemia (Table 4), nor were there any significant associations
between fasting and post-OGTT plasma GO levels and any
microvascular endothelial (dys)function markers (Table 4).
Higher fasting plasma 3-DG levels were associated with higher
plasma microvascular ED scores after adjusting for gender, age and
glucose metabolic status (Table 4, model 1), although this
association was no longer statistically significant after additional
adjustments (Table 4, models 2–3). In line with this, higher post-
OGTT plasma 3-DG levels were associated with higher plasma
microvascular ED scores (Table 4, model 1), an association that was
attenuated, but remained statistically significant, after further
adjustments (Table 4, models 2–3). Surprisingly, higher fasting
plasma 3-DG levels were associated with greater heat-induced
skin hyperaemia responses even in the fully adjusted model
(Table 4, models 1–3), a finding that did not apply to post-OGTTPlease cite this article in press as: Hanssen NMJ, et al. Fasting and po
microvascular, but not macrovascular, disease in individuals with an
(2020), https://doi.org/10.1016/j.diabet.2020.02.002plasma 3-DG levels. Furthermore, higher fasting and post-OGTT
plasma glucose levels were associated with significantly higher
plasma microvascular ED scores (Table 4, models 1–3). Finally, no
consistent interactions were observed with either gender or
glucose metabolic status for these associations (data not shown).
Discussion
Our present study has found, in a population-based observa-
tional cohort study enriched by the inclusion of T2DM patients,
that higher fasting and post-OGTT plasma MGO levels are
associated with markers of CKD and the presence of retinopathy,
but not with prior CVD, ABI or cIMT. Higher plasma MGO levels
were also associated with plasma biomarkers of microvascular ED
and sE-selectin in particular. Associations between post-OGTT and
fasting plasma MGO levels and disease outcomes appear to be of
similar strength. However, no consistent associations with either
plasma GO or 3-DG levels were found.
Nevertheless, these present findings expand our previous work
by evaluating not only fasting, but also post-OGTT, levels of
dicarbonyl stress. This is important as it was previously confirmed
that plasma dicarbonyl levels rise rapidly after OGTT or a mixed
meal [3,9]. Because post-OGTT rather than fasting plasma glucose
levels are more strongly associated with incident CVD [10], our
hypothesis was that any associations with vascular disease would
also be stronger with post-OGTT compared with fasting dicarbonyl
levels. However, our study has found that post-OGTT plasma MGO
levels are, in general, no more strongly associated with vascular
disease than are fasting plasma MGO levels. Likewise, associations
between MGO and albuminuria and a decreased eGFR were
apparently attenuated after adjusting for fasting MGO levels. This
may have been due to the possibility that post-OGTT levels of
plasma dicarbonyls are likely to underestimate the actual peak
plasma dicarbonyl levels reached during the day, as studies usingst-oral-glucose-load levels of methylglyoxal are associated with
d without (pre)diabetes: The Maastricht Study. Diabetes Metab
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glycaemic spikes are more common than previously thought and
are also not consistently reflected by post-OGTT plasma glucose
levels [21].
Although it was previously found that higher fasting plasma
MGO levels are associated with incident CVD in both T1DM and
T2DM [7], our present study could find no such associations with
prior CVD or subclinical markers of atherosclerosis. In fact, an
earlier report found only prospective associations between plasma
MGO levels and cIMT in T2DM [22]. Interestingly, a similar
discrepancy was found for plasma AGEs in which only associations
with incident CVD [23,24], but not with prior CVD, were found
[25]. Therefore, our cross-sectional analyses should be interpreted
with caution.
In contrast to our findings for CVD, the present findings confirm
associations between higher plasma MGO levels and markers of
CKD [7,8], and also demonstrate that these associations not only
apply to T1DM and T2DM, but also to prediabetes (IGM) and NGM.
The present study mostly included individuals with relatively good
metabolic control. This is important as a recent update of the
Veterans Affairs Diabetes Trial (VADT) revealed that the legacy
effect, often attributed in part to glycation [26], was no longer
present in that study [27], leading to speculation that this was
partly due to intensified treatment of cardiovascular risk. Yet, our
present study shows that, among subjects with a high proportion
using antihypertensive, lipid-modifying and glucose-lowering
treatments (Table 1), the associations between MGO and markers
of CKD nevertheless persist.
Preclinical studies have linked MGO to endothelial activation,
impaired vasoreactivity [28–30] and epigenetic changes in
endothelial cells [31]. Although the present report suggests an
association between higher MGO levels and higher levels of plasma
endothelial activation markers, our main finding was an associa-
tion with sE-selectin, whereas previous animal studies reported
increased expression of ICAM and VCAM [29,30]. On the other
hand, an earlier study found that plasma MGO levels were
associated with sICAM and sVCAM in T1DM [7]. Furthermore, there
was no evidence of any associations with other markers of
microvascular dysfunction. Although extrapolation should be done
with caution among these studies, it could be hypothesized that
the type of endothelial injury caused by MGO may differ according
to type of diabetes, insulin sensitivity, control of other metabolic
risk factors and the vascular bed being studied. This is an important
notion, as inhibition of dicarbonyl stress could yield a greater
reduction of vascular complications, depending on the type of
diabetes and severity of metabolic dysregulation.
The major strengths of the present study include its large
sample size, state-of-the-art equipment for estimating plasma
dicarbonyl levels and in-depth phenotyping of vascular function.
However, there are also several limitations. First of all, due to the
cross-sectional nature of the study, no causality can be inferred for
the association between plasma MGO levels and microvascular
disease. Although consistent associations of MGO with albumin-
uria and eGFR were found, the possibility that MGO is a
consequence of kidney failure rather than a cause of such failure
cannot be excluded [32,33]. In addition, the Maastricht Study
mainly includes Caucasians, which should be taken into account
when generalizing our present findings. In addition, a question-
naire was used to assess prior CVD, which may have led to an
underestimation of the associations with this outcome due to
recall bias. However, this may be considered unlikely as no
associations with cIMT and ABI were found. Finally, the present
study did not take into account all chronic conditions linked to
diabetes in which dicarbonyl stress may play a role. It is worth
mentioning diabetic neuropathy in particular, as MGO has been
identified as a potential driver of that condition [34]. Thus, thePlease cite this article in press as: Hanssen NMJ, et al. Fasting and po
microvascular, but not macrovascular, disease in individuals with an
(2020), https://doi.org/10.1016/j.diabet.2020.02.002present study cannot be used to extrapolate any associations
between plasma dicarbonyls and other conditions linked to
(pre)diabetes.
Conclusion
The present study has established that higher plasma MGO
levels both before and after an OGTT are associated with markers of
CKD in subjects with NGM, prediabetes or T2DM. These findings
therefore identify MGO as a potential therapeutic target to reduce
the burden of CKD in the general population, and highlight the
importance of targeting this reactive metabolite with new
compounds.
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